New Stock News | PuraMed's Hong Kong IPO prospectus has expired.

Pulai Pharmaceutical (Jiangsu) Co., Ltd. - B (abbreviated as: Pulai Pharmaceutical) submitted its Hong Kong IPO prospectus on February 13, 2026, which will expire six months later on August 13, 2026. CITIC SEC is the exclusive sponsor for the submission. According to the previous prospectus, Pulai Pharmaceutical is a leading innovative antimicrobial peptide (AMP) therapeutic drug company established in April 2009, focusing on four core treatment areas: anti-infection, metabolic diseases, tumors, and autoimmune diseases. The company is dedicated to addressing significant unmet global health needs through its proprietary breakthrough technology and candidate drugs. As of the last practical date, Pulai Pharmaceutical has nine candidate drugs, including one core product (PL-5) and two major products (PL-3301 and PL-18). Currently, Pulai Pharmaceutical's product pipeline is advancing steadily. PL-5 entered the regulatory filing stage in China in 2024, and a new drug application has been submitted to the National Medical Products Administration's Drug Review Center, while the company is conducting Phase II clinical trials for PL-5 in the United States. PL-3301 and PL-18 are in clinical development, and several preclinical assets are progressing according to their respective development plans.